OBJECTIVE: To evaluate the cost-effectiveness of human papillomavirus (HPV) DNA testing
as a primary screening test in combination with cervical cytology in women aged 30 years or …

Background The availability of human papillomavirus (HPV) DNA testing and vaccination
against HPV types 16 and 18 (HPV-16, 18) motivates questions about the cost-effectiveness …

ContextDespite quality assurance standards, Papanicolaou (Pap) test characteristics remain
less than optimal. ObjectiveTo compare the societal costs and benefits of human …

Objectives Human papillomavirus (HPV) testing is not widely used for triage of equivocal
Pap smears or primary screening in Québec, Canada. Our objective was to evaluate the cost …

In the US, reductions in cervical cancer-related mortality over the past five decades can be
attributed to the implementation of screening programs. US-based guidelines recommend …

Background Despite recommendations from the US Preventive Services Task Force
(USPSTF) regarding the age at which to begin and end cervical cancer screening, as well as …

Please cite this paper as: van Rosmalen J, de Kok I, van Ballegooijen M. Cost‐effectiveness
of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG …

Objective This study addresses the following 3 questions posed by the US Preventive
Services Task Force:(1) at what age should screening for cervical cancer begin;(2) at what …

Background Primary cervical screening with both human papillomavirus (HPV) DNA testing
and cytological examination of cervical cells with a Pap test (cytology) has been evaluated in …

Abstract Background: Consensus United States cervical cancer screening guidelines
recommend use of combination Pap plus human papillomavirus (HPV) testing for women …